LSV Asset Management cut its stake in Organon & Co. (NYSE:OGN – Free Report) by 4.6% in the fourth quarter, HoldingsChannel reports. The firm owned 7,472,429 shares of the company’s stock after selling 362,111 shares during the quarter. LSV Asset Management’s holdings in Organon & Co. were worth $53,577,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Royal Bank of Canada lifted its holdings in Organon & Co. by 53.4% during the 1st quarter. Royal Bank of Canada now owns 360,862 shares of the company’s stock worth $5,374,000 after buying an additional 125,648 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Organon & Co. by 126.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,435,198 shares of the company’s stock worth $21,370,000 after buying an additional 801,307 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Organon & Co. by 2.6% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,042,991 shares of the company’s stock worth $15,530,000 after buying an additional 26,640 shares during the last quarter. Focus Partners Wealth lifted its holdings in Organon & Co. by 33.2% during the 1st quarter. Focus Partners Wealth now owns 55,875 shares of the company’s stock worth $832,000 after buying an additional 13,925 shares during the last quarter. Finally, XTX Topco Ltd purchased a new stake in Organon & Co. during the 2nd quarter worth about $107,000. 77.43% of the stock is currently owned by hedge funds and other institutional investors.
Organon & Co. Stock Up 0.0%
OGN opened at $13.44 on Monday. The business’s 50-day simple moving average is $9.43 and its 200-day simple moving average is $8.25. The company has a debt-to-equity ratio of 9.47, a quick ratio of 1.42 and a current ratio of 1.97. Organon & Co. has a one year low of $5.69 and a one year high of $13.48. The stock has a market capitalization of $3.53 billion, a P/E ratio of 14.45, a price-to-earnings-growth ratio of 1.24 and a beta of 1.57.
Organon & Co. Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Thursday, June 11th. Stockholders of record on Monday, May 11th will be given a dividend of $0.02 per share. The ex-dividend date is Monday, May 11th. This represents a $0.08 dividend on an annualized basis and a dividend yield of 0.6%. Organon & Co.’s payout ratio is 8.60%.
Insider Activity at Organon & Co.
In other news, SVP Lynette Holzbaur bought 26,448 shares of the business’s stock in a transaction dated Wednesday, May 6th. The shares were acquired at an average price of $13.35 per share, for a total transaction of $353,080.80. Following the completion of the transaction, the senior vice president owned 52,851 shares of the company’s stock, valued at approximately $705,560.85. This trade represents a 100.17% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 1.62% of the company’s stock.
Analyst Ratings Changes
OGN has been the subject of a number of recent analyst reports. Barclays lifted their price target on Organon & Co. from $7.50 to $8.00 and gave the stock an “underweight” rating in a report on Tuesday, February 24th. Piper Sandler raised Organon & Co. from an “underweight” rating to a “neutral” rating and lifted their price target for the stock from $5.00 to $14.00 in a report on Tuesday, April 28th. Zacks Research raised Organon & Co. from a “strong sell” rating to a “hold” rating in a report on Tuesday, April 14th. Weiss Ratings raised Organon & Co. from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, May 15th. Finally, Wall Street Zen downgraded Organon & Co. from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. Five investment analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Reduce” and an average price target of $11.40.
Read Our Latest Research Report on OGN
Organon & Co. Profile
Organon & Co is a global healthcare company that was established as an independent, publicly traded entity following its spin-off from Merck & Co in June 2021. Headquartered in Jersey City, New Jersey, Organon focuses on delivering therapeutic solutions across women’s health, biosimilars, and established brands. The company’s creation reflected a strategic effort to concentrate on specialty pharmaceuticals and legacy products with proven patient impact.
In women’s health, Organon provides a broad portfolio of products addressing reproductive and gynecological conditions, including fertility treatments, contraception, and hormone replacement therapies.
Featured Articles
- Five stocks we like better than Organon & Co.
- The Smart Glasses Gold Rush Is Leaving Old-School Eyewear Behind
- 3 Rare Earth Stocks That Win No Matter What China Does Next
- Amylyx Stock: Why the Full Pipeline Story Matters
- Palantir and Dell Build an AI OS for the Paranoid
Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGN – Free Report).
Receive News & Ratings for Organon & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organon & Co. and related companies with MarketBeat.com's FREE daily email newsletter.
